Utilizing Patients-Derived Xenografts

Utilizing Patients-Derived Xenografts and Histological Assessment for Personized Medicine in Oncology

Author: Emmanuel Loeb

Globally, 8.2 million people die each year from cancer, an estimated 13% of all deaths worldwide. There is a 70% increase in the expected new cases of cancer over the next 2 decades. According to the W.H.O, more than 100 cancer types exist, each requiring unique diagnosis and treatment.

Traditional tumor classification, treatment methods and disease prognosis have been a point of debate in the last years. It is very well established that a malignant tumor is a very complex tissue entity and is changing during therapy and disease progression continuously. There is much evidence that patients with identical classification, morphology, mutation type and grade of malignancy could respond differently to the same therapy. Thus, a different approach, of personalized treatment, taking into consideration the patient’s and the tumor’s characteristics is required. Personalized medicine seems to be the most suitable paradigm for oncology patients’ management. In order to achieve an effective personalized therapy the patient and the tumor should be evaluated in advance, both for maximizing the treatment effect and for recovery prediction.

Mouse models, immune deficient, lacking their own immune cells, NSG mice, represent ground-breaking platforms to evaluate compounds to treat a variety of human diseases, from cancer and infectious diseases to allergies, inflammation and Graft versus Host Disease. These animals are implanted with the patient tumor. Animals bearing the human tumor will be examined for several treatments. Analysis of tumor implant can be realized by immunohistological markers. Utilizing Patients Derived Xenografts (PDX) in immune deficient mice, could serve as a tool to predict best choice of medicine per an individual patient. We hope that the combination of involving histological tools in the therapy evaluation process of the xenografts will provide an accurate result and will reduce the time for the patient treatment.

The challenge of this method is to predict a suitable therapy for a specific malignant tumor based on an experimental animal trial using PDX models combined with microscopy evaluations. Sophisticated histological tools can offer an early detection of the therapy effects in the mouse. This will reduce the turn over time and will provide the oncologist with a therapy prediction based on an animal study.

I order to design and develop such a system a preliminary study must be carried out in order to show an accurate prediction of a certain drug in the mouse for the usage of the oncologist in the patient. Patho-Logica is involved with few players in this field with the hope to be part of such a study.

Utilizing Patients-Derived Xenografts and Histological Assessment for Personized Medicine in Oncology

More posts

Bungaro-toxin marker for histology
Bungaro-toxin marker for histology: A powerful tool for the quantification and evaluation of the Acetyl-Choline...
Webinar December 2020
Webinar December 2020 A professional Webinar on the topic: From a Conceptual “Idea” to a...
CNS Models in Rodents
CNS models in rodents: What can you expect from your experimental pathologist? Dr. Emmanuel Loeb...
Calibration of IHC for Covid-19 virus
Calibration of IHC for Covid-19 virus in Golden Syrian Hamsters Dr. Emmanuel loeb, Dr. Zohar...
Digitalization of Pathology
How Artificial Intelligence (AI) and Deep Learning (DL) processes are shaping and influencing the work...
Treatment in Peripheral Nerve Injury
Photobiomodulation Triple Treatment in Peripheral Nerve Injury: Nerve and Muscle Response Mira M. Mandelbaum-Livnat, PhD,1...
Treatment of Experimental Actinic Keratoses
A Hexokinase 2 Modulator for Field-Directed Treatment of Experimental Actinic Keratoses Vered Behar, Hadas Pahima,...
The pros and cons of animal experiments
The pros and cons of animal experiments; an essay on ethical issues Author: Emmanuel Loeb...
The Usage of Animal Models
The Usage of Animal Models for Pre-Clinical Trials: a pathological, comparative approach Author: Emmanuel Loeb....
Technocratic Scientific Empire
Technocratic Scientific Empire – the good, the bad, and the man that could not dream...

Thank you!

Your message has been sent

Skip to content